The pharmaceutical industry plays a central role in modern healthcare and is a driver of medical innovation. Especially in Hamburg, a leading city for life sciences in Germany, a large number of startups are working in the pharma sector. Three of them are presented in this article: GQ Bio Therapeutics, AEP and Topas Therapeutics.
GQ Bio Therapeutics
GQ Bio Therapeutics was founded in 2012 and is a pioneer in the field of gene therapy. The company's central project is the high performance vector platform called HCAd. This platform is designed to address some of the major challenges in gene therapy, including the transfer of large and multiple genes with a single vector, highly efficient gene transfer, and large-scale pharmaceutical manufacturing. GQ Bio Therapeutics' overall focus is on developing breakthrough treatments for chronic and prevalent diseases such as osteoarthritis and disc degeneration.
AEP
AEP is a modern pharmaceutical wholesaler. The company offers permanent top conditions for pharmacies of all sizes and locations. Through a simple ordering and delivery system, AEP enables smooth procurement of medications. Its key corporate values include maximum transparency, a fair price and conditions model, and solution-oriented services. AEP strives to strengthen owner-operated pharmacies, help secure their future, and provide a reliable and honest alternative in the wholesale market.
Topas Therapeutics
Topas Therapeutics is a clinical-stage biopharmaceutical company. Its goal is to develop novel treatments for autoimmune diseases. The company uses a proprietary platform of antigen-specific nanoparticle conjugates called TPCs (Topas Particle Conjugates). This technology aims to restore immune tolerance and target the immune system. Topas Therapeutics has already developed two clinical candidates: TPM203 for the treatment of pemphigus vulgaris in Phase 1 and TPM 502 for the treatment of celiac disease in Phase 2.
